Show simple item record

dc.contributor.authorTAJBER, LIDIAen
dc.contributor.authorEHRHARDT, CARSTENen
dc.contributor.authorPALUCH, KRZYSZTOFen
dc.contributor.authorHEALY, ANNEen
dc.date.accessioned2013-09-03T15:50:53Z
dc.date.available2013-09-03T15:50:53Z
dc.date.issued2013en
dc.date.submitted2013en
dc.identifier.citationTewes F, Paluch KJ, Tajber L, Gulati K, Kalantri D, Ehrhardt C, Healy AM, Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery, European Journal of Pharmaceutics and Biopharmaceutics, 85, 3, 2013, 604 - 613en
dc.identifier.otherYen
dc.descriptionPUBLISHEDen
dc.description.abstractIn a number of pulmonary diseases, patients may develop abnormally viscous mucus reducing drug efficacy. To increase budesonide diffusion within lung fluid, we developed nanoporous microparticles (NPMPs) composed of budesonide and a mucokinetic, ambroxol hydrochloride, to be inhaled as a dry powder. Budesonide/ambroxol-HCl particles were formulated by spray drying and characterised by various physicochemicals methods. Aerodynamic properties were evaluated using a cascade impactor. Drugs apparent permeability coefficients were calculated across mucus producing Calu-3 cell monolayers cultivated at an air?liquid interface. Microparticles made only from budesonide and ambroxol-HCl had smooth surfaces. In the presence of ammonium carbonate ((NH4)2CO3), NPMPs were formulated, with significantly (P < 0.05) superior aerodynamic properties (MMAD = 1.87 ? 0.22 ?m and FPF = 84.0 ? 2.6%). The formation of nanopores and the increase in the specific surface area in the presence of (NH4)2CO3 were mainly attributed to the neutralisation of ambroxol-HCl to form ambroxol base. Thus, ambroxol base could behave in the same manner as budesonide and prompt nanoprecipitation when spray dried from an ethanol/water mix occurs. All formulations were amorphous, which should enhance dissolution rate and diffusion through lung fluid. These NPMPs were able to improve budesonide permeability across mucus producing Calu-3 cell monolayers (P < 0.05) suggesting that they should be able to enhance budesonide diffusion in the lungs through viscous mucusen
dc.format.extent604en
dc.format.extent613en
dc.language.isoenen
dc.relation.ispartofseriesEuropean Journal of Pharmaceutics and Biopharmaceuticsen
dc.relation.ispartofseries85en
dc.relation.ispartofseries3en
dc.rightsYen
dc.subject.otherBudesonide
dc.titleSteroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug deliveryen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/ehrhardcen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/healyamen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/ltajberen
dc.identifier.rssinternalid84289en
dc.identifier.doi10.1016/j.ejpb.2013.03.020en
dc.rights.ecaccessrightsOpenAccess
dc.subject.TCDThemeImmunology, Inflammation & Infectionen
dc.subject.TCDThemeNanoscience & Materialsen
dc.identifier.orcid_id0000-0003-0730-1829en
dc.contributor.sponsorScience Foundation Ireland (SFI)en
dc.identifier.urihttp://hdl.handle.net/2262/67347


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record